Crude Oil (CL)

에 대한 최신 뉴스 Colgate-Palmolive (NYSE:CL) 주식

Colgate-Palmolive

Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.

Earnings

News

Pre-Market Outlook

Markets

금요일 아침 (현지 시간 기준) 미국 주식 선물이 약간 높게 거래되면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: 1. 월스트리트는 오토네이션(NYSE:AN)이 개장 전 분기별 주당 순이익 $4.38와 매출 $67.1억 달러를 보고할 것으로 예상하고 있다. 오토네이션의 주식은 애프터 마켓에서 0.4% 상승하여 $163.81에 거래되었다.

금요일 주목해야 할 주식: 오토네이션, 캐피털 원, 콜게이트 그리고 2종목

Equities

Previews

Tech

Trading Ideas

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Colgate-Palmolive Co

Core One Labs Inc

CHINA LIAONING DINGXU ECO by China Liaoning Dingxu Ecological Agriculture Development, Inc.

China Liaoning Dingxu Ecological Agriculture Development Inc

Clarus Corp

CHAVANT CAPITAL ACQUISITION CORP UNIT 1 COM & 1/3 WT EXP

CLARITAS PHARMACICLS INC by CLARITAS PHARMACEUTICALS INC.

Claritas Pharmaceuticals Inc

Core Laboratories Inc

CALBEE Inc

Columbia Financial Inc

CALIBER ENERGY INC by Caliber Energy, Inc.

Colombier Acquisition Corp. II Class A Ordinary Shares

Colombier Acquisition Corp II

Colombier Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant

Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share

Cellebrite DI Ltd

CHRISTINA LAKE CANNABIS by Christina Lake Cannabis Corp.

Christina Lake Cannabis Corp

CLICKS GROUP LTD S/ADR by Clicks Group Ltd

Clicks Group Ltd

CENTRAL CHINA SECS S/ADR by Central China Securities Co. Ltd.

Calcol Inc

Sinch AB

Cool Co Ltd

CEL Corp

Cell Source Inc

CapitaLand China Trust

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

Direxion Daily Cloud Computing Bull 2X Shares

Chatham Lodging Trust (REIT) Common Shares of Beneficial Interest

Chatham Lodging Trust

Chatham Lodging Trust (REIT) 6.625% Series A Cumulative Redeemable Preferred Shares of Beneficial Interest

Cloud3 Ventures Inc Ordinary Shares (Sub Voting)

CLOUD3 VENTURES INC by CLOUD3 VENTURES INC

Cloud3 Ventures Inc

Calidi Biotherapeutics Inc Warrants (01/01/9999)

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics Inc

Coles Group Ltd

COLES GROUP LTD UNSP/ADR by Coles Group Ltd.

China Liberal Education Holdings Limited - Ordinary Shares

China Liberal Education Holdings Ltd

CONCRETE LEVELING SYS INC by Concrete Leveling Systems Inc.

Concrete Leveling Systems Inc

Cleveland-Cliffs Inc

Clearfield Inc

CLIFFORD MDERN IVING HLD by CLIFFORD MODERN LIVING HLDGS LTD.

CLARITY METALS CORP by Clarity Metals Corp.

Clarity Metals Corp

Aris Mining Corp

CLEGHORN MINERALS ORD by Cleghorn Minerals

Cleghorn Minerals Ltd

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies Ltd

CLEANGO INNOVATIONS INC by CleanGo Innovations Inc.

CleanGo Innovations Inc

CLEAN SEED CAP GROUP LTD by Clean Seed Capital Group Ltd

Clean Seed Capital Group Ltd

Cloud Nine Web3 Technologies Inc

HUTECH21 CO LTD NEW by Hutech21 Co., Ltd.

Hutech21 Co Ltd

Clean Harbors Inc

ClearDAO

CLST Holdings Inc

COLTENE HOLDING AG ORD by Coltene Holding AG

Coltene Holding AG

Tidal Trust II Veridien Climate Action ETF

Energy Plug Technologies Corp

CORDLIFE GROUP LTD ORD by Cordlife Group Ltd

Cordlife Group Ltd

CLS HOLDINGS PLC ORD by CLS Holdings Plc.

CLS Holdings PLC

Click Holdings Ltd

CAPITALAND INVESTMENT LTD by Capitaland Investment Ltd.

CapitaLand Investment Ltd

CLEAN EARTH ACQUISITIONS CORP RT

CLEAN EARTH ACQUISITIONS CORP UNIT 1 CL A COM & 1 RT 1/2 RED WT EXP

CLEAN EARTH ACQUISITIONS CORP RED WT EXP

Global X Funds Global X 1-3 Month T-Bill ETF

ClearSign Technologies Corporation - Common Stock

ClearSign Technologies Corp

CLEARFORD WATER SYS INC by Clearford Water Systems, Inc.

Clearford Water Systems Inc

CLICKSTREAM CORP by ClickStream Corporation

ClickStream Corp

CITY OF LONDON INVST GRP by City of London Investment Group PLC

City of London Investment Group PLC

ProShares Long Online/Short Stores ETF

Clarke Inc

Calcitech Ltd

TWC ENTERPRISES LTD ORD by TWC Enterprises Ltd.

TWC Enterprises Ltd

CLAYTON & LAMBERT MFG CO by Clayton & Lambert Manufacturing Co.

CHALLENGER GOLD LIMITED by Challenger Gold Limited

Challenger Gold Ltd

COLLINS FOODS LTD NWMKT by Collins Foods Ltd Newmarket Qld

Collins Foods Ltd

BICO Group AB

COLLECTIVE METALS INC by COLLECTIVE METALS INC.

Collective Metals Inc

CELLNEX TELECOM UNSP/ADR by Cellnex Telecom SA

Cellnex Telecom SA

Cellectis S.A. - American Depositary Shares

Cellectis SA

CALLINEX MINES INC by Callinex Mines Inc.

Callinex Mines Inc

Cornerstone Strategic Investment Fund, Inc. Common Shares

Cornerstone Strategic Value Fund Inc

Climb Global Solutions, Inc. - Common Stock

Climb Global Solutions Inc

CALIMA ENERGY LTD NEW by Calima Energy Ltd.

Calima Energy Ltd

CALGRO M3 HOLDINGS LTD by Calgro M3 Holdings Ltd.

Calgro M3 Holdings Ltd

Climeon AB

CANADIAN PREM SAND by Canadian Prem Sand Inc.

Canadian Premium Sand Inc

Calumet Inc

Clean Energy Fuels Corp

CALIAN GROUP LTD ORD by Calian Group Ltd.

Calian Group Ltd

Clene Inc

NYLI Cleaner Transport ETF

CLEAN VISION CORPORATION by Clean Vision Corporation

Clean Vision Corp

CELLNEX TELECOM SA ORD by Cellnex Telecom SA

Callisto - United States Dollar

iShares AAA CLO Active ETF

CloakCoin

VanEck ETF Trust VanEck AA-BB CLO ETF

JP Morgan analyst Andrea Teixeira maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $109 to $103.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $103

Colgate-Palmolive's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) short percent of float has risen 4.59% since its last report. The company recently reported that it has 9.29 million shares sold short, which is 1.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Colgate-Palmolive Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736538310_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Colgate-Palmolive has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Colgate-Palmolive's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Colgate-Palmolive's peer group average for short interest as a percentage of float is 6.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Colgate-Palmolive's Recent Short Interest

TD Cowen analyst Robert Moskow maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Buy and lowers the price target from $110 to $100.

TD Cowen Maintains Buy on Colgate-Palmolive, Lowers Price Target to $100

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Colgate-Palmolive and provided 12-month price targets. The average target is $102.0, accompanied by a high estimate of $114.00 and a low estimate of $83.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.27%. 
<img src="https://www.benzinga.com/files/images/story/2025/1736272811_0_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Colgate-Palmolive by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$83.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$92.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$101.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$113.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Colgate-Palmolive. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Colgate-Palmolive compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Colgate-Palmolive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Colgate-Palmolive's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Colgate-Palmolive analyst ratings.</a>
<h2>Unveiling the Story Behind Colgate-Palmolive</h2>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>Financial Insights: Colgate-Palmolive</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Colgate-Palmolive's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.4% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Colgate-Palmolive's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.64% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Colgate-Palmolive's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 264.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Colgate-Palmolive's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.43%, the company showcases efficient use of assets and strong financial health.
Debt Management: Colgate-Palmolive's debt-to-equity ratio stands notably higher than the industry average, reaching 19.39. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Colgate-Palmolive In The Eyes Of 6 Experts

Wells Fargo analyst Chris Carey maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Underweight and lowers the price target from $92 to $83.

Wells Fargo Maintains Underweight on Colgate-Palmolive, Lowers Price Target to $83

WIIM

Colgate-Palmolive shares are trading lower after Piper Sandler maintained an Overweight rating on the stock but lowered its price target from $121 to $112.

Piper Sandler analyst Korinne Wolfmeyer maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $121 to $112.

Piper Sandler Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $112

<a href="https://www.bloomberg.com/news/articles/2024-11-19/tom-s-of-maine-toothpaste-has-a-bacteria-problem-fda-finds" title="https://www.bloomberg.com/news/articles/2024-11-19/tom-s-of-maine-toothpaste-has-a-bacteria-problem-fda-finds">https://www.bloomberg.com/news/articles/2024-11-19/tom-s-of-maine-toothpaste-has-a-bacteria-problem-fda-finds</a>
US inspectors found Tom's of Maine toothpaste was made with water containing multiple strains of dangerous bacteria and sold to consumers anyway, according to a warning letter posted Tuesday.

'Tom's of Maine Toothpaste Has a Bacteria Problem, FDA Finds' - Bloomberg News

Cresco Labs Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#CSE">CL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>) (FSE: 6CQ) a company behind Sunnyside dispensaries, released its financial and operating results on Friday for the third quarter ended September 30, 2024.
"So far this year, we've generated $103 million in operating cashflow, enabling us to reinvest in our core, and to explore new markets and growth verticals, all while improving our balance sheet and paying down debt," CEO and co-founderCharlie Bachtell said.
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
<ul>
<li>Third quarter revenue of $179.8 million representing a 3.2% sequential drop and a 5.7% decrease from the same quarter of last year.</li>
<li>Gross profit of $93.4 million, compared to a $93.6 million gross profit in the corresponding period of last year, and $94.8 million gross profit in the previous period.</li>
<li>Adjusted gross profit, a non-GAAP measure, was $95.3 million, and an adjusted gross margin of 53% of revenue, a 250 bps improvement year-over-year.</li>
<li>Selling, general and administrative expenses of $57 million. Reduced adjusted SG&amp;A by 6% year-over-year to $53 million, or 30% of revenue.</li>
<li>Net loss was $7.7 million, down 93% year-over-year and 84% quarter-over-quarter.</li>
<li>Third quarter Adjusted EBITDA came in positive at $51 million, up 5% year-over-year; Adjusted EBITDA margin of 29%, a 280 bps improvement year-over-year.</li>
<li>Record third-quarter operating cash flow of $49 million and free cash flow of $43 million.</li>
<li>Adjusted EBITDA, a non-GAAP measure, came in positive at $51.3 million, down from an adjusted EBITDA gain of $49 million in the prior year's period and $53.9 million in the prior quarter.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40259646/cannabis-co-cresco-labs-q2-gross-profit-increases-over-9-yoy-reports-nearly-7-drop-in-revenue">Cannabis Co. Cresco Lab&#8217;s Q2 Gross Profit Increases Over 9% YoY, Reports Nearly 7% Drop In Revenue</a>
As of Sept. 30, 2024, assets were $312 million, including cash, cash equivalents and restricted cash of $157 million.
The company had senior secured term loan debt, net of discount and issuance costs, of $390 million and a mortgage loan, net of discount and issuance costs of $18 million.
On Oct. 25, 2024, the company repurchased a $40 million principal amount of its senior loan and paid $0.3 million of accrued Interest.
Cresco Labs made its debut in Chicago in 2013 when Illinois passed the Compassionate Use of Medical Cannabis Act. &#8220;The company's goal and that of its management team has been to help normalize and professionalize this industry,&#8221; Bachtell told the crowd gathered at the <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a> <a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c" target="_blank" rel="noreferrer noopener">in Chicago in early October.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40779975/is-cresco-labs-an-overlooked-cannabis-stock-market-potential-in-ohio-florida-pennsy">Is Cresco Labs An Overlooked Cannabis Stock? Market Potential In Ohio, Florida &amp; Pennsylvania Promise Opportunity</a></li>
</ul>

Cannabis

CRLBF

CSE:CL

Cannabis Co. Cresco Labs' 93% YoY Improvement In Net Loss, $49M Operating Cash Flow In Q3

On November 7, it was revealed in an SEC filing that STANLEY SUTULA III, Chief Financial Officer at Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000021665/000122520824009716//Archives/edgar/data/21665/000122520824009716/0001225208-24-009716-index.htm">U.S. Securities and Exchange Commission</a> on Thursday revealed that III, Chief Financial Officer at Colgate-Palmolive in the Consumer Staples sector, exercised stock options for 45,410 shares of CL stock. The exercise price of the options was $77.04 per share.
The Friday morning update indicates Colgate-Palmolive shares up by 0.94%, currently priced at $95.15. At this value, III's 45,410 shares are worth $822,375.
<h3>Delving into Colgate-Palmolive's Background</h3>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>Understanding the Numbers: Colgate-Palmolive's Finances</h3>
Positive Revenue Trend: Examining Colgate-Palmolive's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.4% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 61.08%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Colgate-Palmolive's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.9.
</li>
</ul>
Debt Management: Colgate-Palmolive's debt-to-equity ratio surpasses industry norms, standing at 19.39. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 26.08 is lower than the industry average, implying a discounted valuation for Colgate-Palmolive's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.72 is above industry norms, reflecting an elevated valuation for Colgate-Palmolive's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 17.77, Colgate-Palmolive demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000021665">Check Out The Full List Of Colgate-Palmolive's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Unloading: STANLEY SUTULA III Sells Options, Realizes $822K

In a new SEC filing on November 5, it was revealed that III, Chief Financial Officer at Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), executed a significant exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000021665/000122520824009620//Archives/edgar/data/21665/000122520824009620/0001225208-24-009620-index.htm">U.S. Securities and Exchange Commission</a>, III, Chief Financial Officer at Colgate-Palmolive, exercised stock options for 50,000 shares of CL. The transaction value amounted to $905,500.
The Wednesday morning update indicates Colgate-Palmolive shares up by 0.94%, currently priced at $95.15. At this value, III's 50,000 shares are worth $905,500.
<h3>Unveiling the Story Behind Colgate-Palmolive</h3>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>Colgate-Palmolive's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Colgate-Palmolive showcased positive performance, achieving a revenue growth rate of 2.4% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 61.08%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.9, Colgate-Palmolive showcases strong earnings per share.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 19.39, caution is advised due to increased financial risk.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 27.09, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.87, Colgate-Palmolive's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 18.39 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Closer Look at Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000021665">Check Out The Full List Of Colgate-Palmolive's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

At Colgate-Palmolive, STANLEY SUTULA III Chooses To Exercise Options, Resulting In $905K

Wells Fargo analyst Chris Carey maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Underweight and lowers the price target from $100 to $92.

Comments

Colgate-Palmolive

뉴스

에 대한 최신 뉴스 Colgate-Palmolive (NYSE:CL) 주식

금요일, 10월 25, 2024

일요일, 7월 21, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌